{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:37:29Z","timestamp":1774341449937,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T00:00:00Z","timestamp":1442620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00520-015-2941-0","type":"journal-article","created":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T05:56:55Z","timestamp":1442642215000},"page":"1583-1594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy\u2014a systematic review"],"prefix":"10.1007","volume":"24","author":[{"given":"Ricardo","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habeeb","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed FK","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,19]]},"reference":[{"key":"2941_CR1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790\u2013803","journal-title":"Nat Rev Drug Discov"},{"key":"2941_CR2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"L. Charles","year":"2011","unstructured":"Charles L (2011) Loprinzi et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"2941_CR3","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"Henri Roch\u00e9","year":"2006","unstructured":"Roch\u00e9 H et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664\u20135671","journal-title":"J Clin Oncol"},{"key":"2941_CR4","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381\u20135387","journal-title":"J Clin Oncol"},{"key":"2941_CR5","doi-asserted-by":"crossref","unstructured":"Miguel Martin et al. (2005) Adjuvant Docetaxel for Node-Positive Breast Cancer. NEJM 352;22","DOI":"10.1056\/NEJMoa043681"},{"key":"2941_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","volume":"3","author":"RE Smith","year":"2002","unstructured":"Smith RE, Anderson SJ, Brown A, et al. (2002) Phase II trial doxorrubicin\/docetaxel\/cyclophosphamide for locally advanced and metastatic breast cancer: results from nsabp trial BP-58. Clin Breast Cancer 3:333\u2013340","journal-title":"Clin Breast Cancer"},{"key":"2941_CR7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.23321","volume":"112","author":"Edgardo Rivera","year":"2008","unstructured":"Rivera E et al. (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455","journal-title":"Cancer"},{"key":"2941_CR8","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from nsabp B-28. J Clin Oncol 23:3686\u20133696","journal-title":"J Clin Oncol"},{"key":"2941_CR9","first-page":"3611","volume":"27","author":"J. William","year":"2009","unstructured":"William J, Gradishar A, et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic. Breast Cancer J Clin Oncol 27:3611\u20133619","journal-title":"Breast Cancer J Clin Oncol"},{"key":"2941_CR10","unstructured":"Ian F. Tannock et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial"},{"issue":"4","key":"2941_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.v17i4.562","volume":"17","author":"S. Saibil","year":"2010","unstructured":"Saibil S et al. (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17(4):42\u201347","journal-title":"Curr Oncol"},{"issue":"7","key":"2941_CR12","doi-asserted-by":"crossref","first-page":"p 175","DOI":"10.1016\/S1359-6349(10)72259-X","volume":"8","author":"S Damaraju","year":"2010","unstructured":"Damaraju S, Ghosh S, Tuszynski J, Greiner R, Lai R, Cass C, Mackey J (2010) JCYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy. European J of Cancer 8(7):p 175","journal-title":"European J of Cancer"},{"issue":"24","key":"2941_CR13","first-page":"p258s","volume":"70","author":"S Damaraju","year":"2010","unstructured":"Damaraju S, Sehrawat BS, Ghosh S, Pituskin E, Tuszynski J, Cass CE, Mackey JR (2010) Germline Copy Number Polymorphisms Associated with Toxicity from Adjuvant Docetaxel. Cancer Research 70(24):p258s","journal-title":"Cancer Research"},{"key":"2941_CR14","doi-asserted-by":"crossref","unstructured":"Shim A et al (2005) The safety and efficacy of second-line single docetaxel (75\u00a0mg\/m2) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy. Cancer Res Treat 37(6):339\u2013343","DOI":"10.4143\/crt.2005.37.6.339"},{"key":"2941_CR15","doi-asserted-by":"crossref","unstructured":"Wang Y et al (2014) A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3\u00a0weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. BMC Cancer. 14:937","DOI":"10.1186\/1471-2407-14-937"},{"key":"2941_CR16","doi-asserted-by":"crossref","unstructured":"Bois D et al. (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320\u20131329","DOI":"10.1093\/jnci\/djg036"},{"key":"2941_CR17","doi-asserted-by":"crossref","unstructured":"Sarris AH et al. (1996) Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 14(1):233\u2013239","DOI":"10.1200\/JCO.1996.14.1.233"},{"key":"2941_CR18","doi-asserted-by":"crossref","unstructured":"Markman M, Kennedy A, Webster K, et al (1999) Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72:100\u2013101","DOI":"10.1006\/gyno.1998.5226"},{"key":"2941_CR19","doi-asserted-by":"crossref","unstructured":"Martoni A, Zamagni C, Gheka A, et al (1993) Antihistamines in the treatment of Taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 85:676","DOI":"10.1093\/jnci\/85.8.676"},{"key":"2941_CR20","doi-asserted-by":"crossref","unstructured":"Van Deventer H, Bernard S. Use of gabapentin to treat taxane-induced arthralgias and myalgias.DOI:10.1200\/Jco.2004.99.298","DOI":"10.1200\/JCO.2004.99.298"},{"key":"2941_CR21","doi-asserted-by":"crossref","unstructured":"Van Deventer H (1999) Use of Gabapentin to treat taxane-induced myalgias. Jco 17(1) January:434\u2013435","DOI":"10.1200\/JCO.1999.17.1.434a"},{"key":"2941_CR22","doi-asserted-by":"crossref","unstructured":"Imai A et al. (2012) Proposed medications for taxane-induced myalgia and arthralgia. Oncology Letters 3:1181\u20131185","DOI":"10.3892\/ol.2012.651"},{"key":"2941_CR23","doi-asserted-by":"crossref","unstructured":"Strasser F, Demmer R, B\u00f6hme C, Schmitz SF, Thuerlimann B, Cerny T, Gillessen S (2008) Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 13:337\u2013346","DOI":"10.1634\/theoncologist.2007-0217"},{"key":"2941_CR24","unstructured":"Fujiwara H. (2001) Prevention of arthralgias and myalgias from paclitaxel andCBDCA combination chemotherapy with shakuyaku-kanzo-to and L-glutamine. Proc Am Soc Clin Oncol 20:299b, (abstr 2948)"},{"key":"2941_CR25","unstructured":"Higgins JPT, Green S. (2011) (editors). Cochrane Handbook for Systematic Reviews of Intreventions Version 5.1.0. The Cochrane Collaboration"},{"key":"2941_CR26","unstructured":"Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, et al. (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1(4):274\u2013278"},{"issue":"12","key":"2941_CR27","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","volume":"120","author":"AD Leal","year":"2014","unstructured":"Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. (2014) North Central cancer treatment group\/alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120(12):1890\u20131897","journal-title":"Cancer"},{"key":"2941_CR28","doi-asserted-by":"crossref","unstructured":"Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17(10):3038\u20133047","DOI":"10.1200\/JCO.1999.17.10.3038"},{"key":"2941_CR29","doi-asserted-by":"crossref","unstructured":"Rick O, Beyer J, Schwella N, Schubart H, Schleicher J, Siegert W (2001) Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 12(8):1151\u20131155","DOI":"10.1023\/A:1011628900089"},{"key":"2941_CR30","doi-asserted-by":"crossref","unstructured":"Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22(9):1767\u20131769","DOI":"10.1200\/JCO.2004.99.298"},{"key":"2941_CR31","doi-asserted-by":"crossref","unstructured":"Higgins Julian PT, Altman Douglas G, G\u00f8tzsche Peter C, Peter J, David M, Oxman Andrew D, et al (2011) The Cochrane Collaboration\u2019s Tool for Assessing Risk of Bias in Randomised Trials. BMJ 343:d5928","DOI":"10.1136\/bmj.d5928"},{"key":"2941_CR32","doi-asserted-by":"crossref","unstructured":"Ryan M, Franke, et al (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562\u20134567","DOI":"10.1200\/JCO.2010.30.7025"},{"key":"2941_CR33","doi-asserted-by":"crossref","unstructured":"Bahl A et al. (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402\u20132408","DOI":"10.1093\/annonc\/mdt194"},{"key":"2941_CR34","doi-asserted-by":"crossref","unstructured":"Kuchuk I et al. (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101\u2013107","DOI":"10.1007\/s10549-013-2727-3"},{"key":"2941_CR35","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Hoshiai H, Noda K (2001) Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin (letter). Gynecol Oncol 81:333\u2013334","DOI":"10.1006\/gyno.2001.6168"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2941-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2941-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2941-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:29:28Z","timestamp":1567193368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2941-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,19]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2941"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2941-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,19]]}}}